DI-Leu16-IL2

N/A

Report date: 2024/07/05 11:15:11

Base Information

Drug NameDI-Leu16-IL2
Drug Alias NameDI-Leu16-IL2SNG-2005SNG2005
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 receptor agonistsAnti-CD20
TargetsInterleukin-2 receptorB-lymphocyte antigen CD20
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaNeoplasms, Gonadal TissueLymphoma, Large-Cell, Anaplastic +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Shenogen Biomedical Co Ltd
Inactive CompaniesNational Cancer InstituteAlopexx Oncology Llc
Active IndicationsLymphoma, B-Cell
Inactive IndicationsWaldenstrom MacroglobulinemiaNeoplasms, Gonadal TissueLymphoma, Large-Cell, Anaplastic +[9] 

Other Information

ATC CodeN/A
Related LinksN/A